Paul Campanelli - Endo International Insider

Endo International plc -- USA Stock  

USD 7.81  0.07  0.89%

President CEO, Director

Mr. Paul V. Campanelli serve as President, Chief Executive Officer, Director of the Company. Mr. Campanelli joined Endo in 2015 as the President of Par Pharmaceutical, leading Endos fully integrated U.S. Generics business, following Endos acquisition of Par Pharmaceutical. Prior to joining Endo, he had served as Chief Executive Officer of Par Pharmaceutical Companies, Inc. following the companys September 2012 acquisition by TPG. While CEO of Par, Mr. Campanelli built a strong leadership team and an industryleading generics business. Under his leadership, the company significantly increased total revenue, acquired Michiganbased JHP Pharmaceuticals, established a business office in London to serve as Pars entry point into the European generics market and completed its acquisition of an active pharmaceutical ingredients facility located in Chennai, India. Prior to the TPG acquisition, Mr. Campanelli served as Chief Operating Officer and President of Par Pharmaceutical, Inc., the companys generics division, from 2011 to 2012. Earlier in his tenure at Par, Mr. Campanelli held roles of increasing responsibility, including Senior Vice President, Business Development Licensing Executive Vice President and President of Par Pharmaceutical, Inc. and was named a Corporationrationrate Officer by Pars board of directors. He also served on the board of directors of Sky Growth Holdings Corporationrationration. Prior to joining Par, Mr. Campanelli served as Vice President, Business Development at Dr. Reddys Laboratories Ltd. where he was employed from 19922001
Age: 53  CEO Since 2016      
353 1 268 2000  http://www.endo.com
Campanelli earned his BS degree from Springfield College.

Paul Campanelli Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 2.42 % which means that it generated profit of $2.42 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (124.07) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 8.28 B in liabilities. Endo International plc has Current Ratio of 1.0 suggesting that it is not liquid enough and may have problems to pay out its financial obligations when they are due.

Similar Executives

Found 1 records

CEO Since

Brenton SaundersAllergan plc
2016

Entity Summary

Endo International plc develops, manufactures, and distributes pharmaceutical solutions and devices worldwide. Endo International plc (ENDP) is traded on NASDAQ in USA. It is located in IRELAND and employs 6,406 people. Endo International is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Pair Correlation Now
   

Pair Correlation

Compare performance and examine historical correlation between any two equity instruments
Hide  View All  NextLaunch Pair Correlation
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Endo International plc to your portfolio

Top Management

Endo International plc Leadership Team
Camille Farhat, President, MBA
Paul Campanelli, CEO
William Spengler, Director
Arthur Higgins, Director
Brian Lortie, President
Donald DeGolyer, CEO
William Montague, Director
Jill Smith, Director
Rajiv Silva, CEO
Michael Hyatt, Director
Douglas Ingram, Director
Antonio Pera, President, MBA
Roger Kimmel, Chairman
Susan Hall, EVP, Ph.D
Sharad Mansukani, Director
Blaise Coleman, President, MBA
Suketu Upadhyay, CFO, CPA
Terrance Coughlin, President
Nancy Hutson, Director
Todd Sisitsky, Director, MBA
Matthew Maletta, President
Shane Cooke, Director
Craig Paterson, Executive, MBA

Stock Performance

Endo International Performance Indicators